Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17123402 | 0.82 | BCHE (0.34) | CTHBCHEACHEKDM4ECYP3A4 | |
| SCHEMBL17124648 | 0.80 | CTH (0.38) | CTHKDM4ECYP3A4 | |
| Hydrochloric Acid SCHEMBL15558384 | 0.74 | KDM4E (0.39) | KDM4ECYP3A4 | |
| SCHEMBL28204300 | 0.73 | — | — | |
| SCHEMBL15559087 | 0.70 | CTH (0.51) | CTHBCHEACHE | |
| SCHEMBL15598121 | 0.69 | CTH (0.46) | CTHBCHEACHEHRH3 | |
| SCHEMBL15598123 | 0.69 | CTH (0.46) | CTHBCHEACHEHRH4HRH3 | |
| SCHEMBL17123404 | 0.67 | LMNA (0.33) | KDM4ECYP3A4 | |
| SCHEMBL15617021 | 0.66 | CTH (0.39) | CTH | |
| SCHEMBL15598125 | 0.66 | CTH (0.42) | CTHBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | SOVA PHARMACEUTICALS, INC. | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150272934-A1 | USE OF CSE INHIBITORS FOR THE TREATMENT OF CUTANEOUS INJURIES OR CONDITIONS AND SLEEP-RELATED BREATHING DISORDERS | HIF1AN, CBS, COXFA4L2 | CTH 4/4885BCHE 152/4885ACHE 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.